VX18-445-106-Part B: A Phase 3, Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age